MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Period	Debt/Equity
2021-12-31	0.08
2022-12-31	0.13
2023-12-31	0.16
2024-12-31	0.16

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MXCT	$0.75	+6.29%	0.72M
3
4
5

MaxCyte Inc. (MXCT) Debt to Equity Ratio

Debt to Equity Ratio Data

Get MaxCyte Inc. Data in Excel

More MXCT Financial Data